



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: SCH-1810

the patent application of

WEISS, BERTRAM et al.

Serial No. 09/867,753

Filed: May 31, 2001

For: HUMAN PEM AS A TARGET FOR BIRTH CONTROL AND TREATMENT OF ALZHEIMER'S
DISEASE

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently
herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37
C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the
attached computer readable copy of the Sequence Listing, submitted in
accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same;
and

3. all statements made herein of their own knowledge are
true and that all statements made on information and belief are believed to
be true; and further, that these statements were made with the knowledge
that willful false statements and the like so made are punishable by fine
or imprisonment, or both, under Section 1001 of Title 18 of the United

Example

The expression of the human PEM in various brain tissues was analyzed by semi-quantitative PCR. To this end, the following primers were used:

Sense 5'-ATGGCGCGTTCGCTCGTCCACGAC-3', (SEQ ID NO 4)

Antisense 5'-TAGTCCACGACGATGTAGACACAG-3'. (SEQ ID NO 5)

In the control, specific primers for beta-actin were used:

Sense primer 5'-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3', (SEQ ID NO 6)

Antisense primer 5'-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3'. (SEQ ID NO 6)

The cDNA was acquired by Invitrogen (Carlsbad, CA, USA).


The PCR analysis was performed with the Advantage-2 PCR kit (Clontech). The reaction conditions were as follows: initially 5 minutes at 95°C; then 30 cycles with 95°C for 30 seconds, 62°C for 30 seconds and 72°C for 1 minute; finally 72°C for 7 minutes. The results show an elevated expression of human PEM in the frontal and temporal lobes in Alzheimer patients in comparison to healthy tissue.

Serial No. 09/867,753

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Aug. 30, 2001
Date


James A. Coburn

HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021